Literature DB >> 26037792

Intraoperative detection of viable bone with fluorescence imaging using Visually Enhanced Lesion Scope in patients with bisphosphonate-related osteonecrosis of the jaw: clinical and pathological evaluation.

D Yoshiga1, M Sasaguri, K Matsuo, S Kokuryou, M Habu, M Oda, M Kodama, H Tsurushima, O Sakaguchi, T Sakurai, J Tanaka, Y Morimoto, I Yoshioka, K Tominaga.   

Abstract

UNLABELLED: There is no standard surgical protocol of bisphosphonate-related osteonecrosis of the jaws (BRONJ), because of the impossibility to visualize this feature intraoperatively. The aim of this study was to introduce how to provide preoperative labeling of the viable bone with minocycline bone fluorescence technique (MBFT) by using VELscope® and investigate histopathologically.
INTRODUCTION: The American Association of Oral and Maxillofacial Surgeons (AAOMS) and the Japanese Society of Oral and Maxillofacial Surgeons (JSOMS) now recommend a more conservative treatment strategy. There is no standard surgical protocol of bisphosphonate-related osteonecrosis of the jaws (BRONJ) because of the impossibility to visualize this feature intraoperatively. The aim of this study was to introduce a mechanism providing preoperative labeling of a viable bone using minocycline bone fluorescence technique (MBFT) with VELscope® and to histopathologically investigate.
METHODS: This report describes a surgical technique used in six patients with BRONJ who underwent jawbone resection under minocycline bone fluorescence imaging using VELscope®. Subsequently, we investigated and compared the clinical findings using VELscope® and histopathological findings.
RESULTS: Histopathological examinations showed that the non-fluorescent moiety was consistent with the BRONJ lesions.
CONCLUSIONS: The surgical treatments that were exactly performed using MBFT with VELscope® offered successful management of BRONJ. This bone fluorescence helped to define the margins of resection, thus improving surgical therapy for extended osteonecrosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26037792     DOI: 10.1007/s00198-015-3096-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  49 in total

1.  Fluorescent tetracycline labeling as an aid to debridement of necrotic bone in the treatment of chronic osteomyelitis.

Authors:  Laurence E Dahners; Gary D Bos
Journal:  J Orthop Trauma       Date:  2002-05       Impact factor: 2.512

2.  Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis.

Authors:  Alberto Bedogni; Giorgia Saia; Giordana Bettini; Anita Tronchet; Andrea Totola; Giorgio Bedogni; Giuseppe Ferronato; Pier Francesco Nocini; Stella Blandamura
Journal:  Oral Oncol       Date:  2011-03-24       Impact factor: 5.337

3.  Molecular mechanisms of glucocorticoid-induced osteoporosis.

Authors:  D Patschan; K Loddenkemper; F Buttgereit
Journal:  Bone       Date:  2001-12       Impact factor: 4.398

4.  Tetracycline bone fluorescence: a valuable marker for osteonecrosis characterization and therapy.

Authors:  Christoph Pautke; Florian Bauer; Oliver Bissinger; Thomas Tischer; Kilian Kreutzer; Timm Steiner; Jochen Weitz; Sven Otto; Klaus-Dietrich Wolff; Stephen R Stürzenbaum; Andreas Kolk
Journal:  J Oral Maxillofac Surg       Date:  2010-01       Impact factor: 1.895

5.  Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy.

Authors:  G Favia; G P Pilolli; E Maiorano
Journal:  Bone       Date:  2009-05-18       Impact factor: 4.398

6.  Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.

Authors:  M A Dimopoulos; E Kastritis; C Bamia; I Melakopoulos; D Gika; M Roussou; M Migkou; E Eleftherakis-Papaiakovou; D Christoulas; E Terpos; A Bamias
Journal:  Ann Oncol       Date:  2008-08-09       Impact factor: 32.976

7.  Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis.

Authors:  Allesandro Agrillo; Claudio Ungari; Fabio Filiaci; Paolo Priore; Giorgio Iannetti
Journal:  J Craniofac Surg       Date:  2007-09       Impact factor: 1.046

8.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

Review 9.  A review of bisphosphonate-associated osteonecrosis of the jaws and its management.

Authors:  David K Lam; George K B Sándor; Howard I Holmes; A Wayne Evans; Cameron M L Clokie
Journal:  J Can Dent Assoc       Date:  2007-06       Impact factor: 1.316

10.  Prognosis factors in the treatment of bisphosphonate-related osteonecrosis of the jaw - Prognostic factors in the treatment of BRONJ.

Authors:  Daigo Yoshiga; Ikuo Nakamichi; Yoshihiro Yamashita; Noriaki Yamamoto; Kensuke Yamauchi; Shinnosuke Nogami; Takeshi Kaneuji; Sho Mitsugi; Kenkou Tanaka; Yoshihiro Kataoka; Takuma Sakurai; Hiroyasu Kiyomiya; Ikuya Miyamoto; Tetsu Takahashi
Journal:  J Clin Exp Dent       Date:  2014-02-01
View more
  3 in total

1.  Fluorescent tetracycline bone labeling as an intraoperative tool to debride necrotic bone during septic hip revision: a preliminary case series.

Authors:  Ernesto Muñoz-Mahamud; Jenaro Ángel Fernández-Valencia; Andreu Combalia; Laura Morata; Álex Soriano
Journal:  J Bone Jt Infect       Date:  2021-01-27

2.  Differences between auto-fluorescence and tetracycline-fluorescence in medication-related osteonecrosis of the jaw-a preclinical proof of concept study in the mini-pig.

Authors:  Oliver Ristow; Dirk Nehrbass; Stephan Zeiter; Daniel Arens; Julius Moratin; Christoph Pautke; Jürgen Hoffmann; Christian Freudlsperger; Sven Otto
Journal:  Clin Oral Investig       Date:  2020-05-22       Impact factor: 3.573

Review 3.  The Therapeutic Effectiveness Using Fluorescence-Guided Surgery for MRONJ.

Authors:  Hongyuan Huang; Ning Zhao; Qingxiang Li; Qiao Qiao; Jianya Zhang; Chuanbin Guo; Yuxing Guo
Journal:  Biomed Res Int       Date:  2022-09-17       Impact factor: 3.246

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.